First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery

MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigatioAds Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
Over 20 drept i gjengangrep i Haiti
SV foreslår å droppe kampen mot EØS-avtalen

Markus Reinisch (Meta): “Vi spiego una volta per tutte perché l’Europa sull’IA rischia di restare indietro”
Vinho vive alta em SP; conheça botecos, wine-bares e lojas que vendem a bebida até em caixa